Sermorelin for Pediatric GHD: Off-Label Use, Monitoring, and What Mothers Need to Know

What Is Sermorelin and Why Is Its Pediatric Use "Off-Label"?

Sermorelin acetate is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and prompts your child's own pituitary gland to produce and secrete growth hormone, rather than replacing GH directly. That distinction matters clinically because the pituitary's natural feedback loop stays intact, which is thought to reduce the risk of GH excess.

The FDA originally approved sermorelin (Geref) for the diagnosis and treatment of pediatric growth hormone deficiency (GHD) in children with open epiphyses. Sertraline's manufacturer, Serono, voluntarily withdrew Geref from the US market in 2008 for commercial reasons unrelated to safety. No new sermorelin product has received pediatric GHD approval since. Every prescriber writing sermorelin for a child today is writing an off-label prescription, and every parent considering it deserves to understand exactly what that means.

Off-label prescribing is legal and common in pediatric medicine, where trials in children are frequently absent or underpowered. The American Academy of Pediatrics estimates that 50 to 75 percent of drugs used in children lack pediatric labeling. Sermorelin is not unusual in that regard, but the absence of a current FDA indication does place the burden of monitoring and informed consent more squarely on the prescribing clinician and the family.

How It Differs From Recombinant Human Growth Hormone

Recombinant human GH (rhGH, brand names Norditropin, Genotropin, Humatrope) is FDA-approved for pediatric GHD and remains the standard of care in most pediatric endocrinology practices. Sermorelin's proposed advantages over rhGH include lower cost, preservation of pituitary feedback, and a shorter half-life that some clinicians argue reduces the risk of supraphysiologic GH levels. The evidence comparing the two head-to-head in children is limited. A 1997 multicenter randomized trial published in the Journal of Clinical Endocrinology and Metabolism found that sermorelin produced first-year growth velocity gains comparable to rhGH in prepubertal children with GHD, though the sermorelin group showed slightly lower IGF-1 elevations.

What "GRADE Moderate" Evidence Actually Means for You

GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) is the system major guideline bodies use to rate the certainty of evidence. GRADE moderate means the true effect is likely close to the estimated effect, but important uncertainty remains. For sermorelin in pediatric GHD, short-term linear growth acceleration receives a GRADE moderate rating based on several randomized controlled trials from the 1990s. Long-term adult height outcomes receive a GRADE low rating because most trials ended before epiphyseal closure. Parents should weigh this gap openly with the prescribing endocrinologist.

Who Gets Diagnosed With Pediatric GHD and How?

Pediatric GHD affects an estimated 1 in 3,800 children in the United States. The diagnosis requires a combination of auxological criteria (height below the 3rd percentile, growth velocity below the 25th percentile for age and sex), bone age assessment, and stimulated GH testing. The Endocrine Society's 2016 Clinical Practice Guideline on GHD recommends that a GH peak below 10 ng/mL on two pharmacologic stimulation tests supports the diagnosis, though cutoffs vary by assay.

Sex-Specific Differences in GHD Diagnosis

Girls and boys with GHD differ in important ways that affect both diagnosis and treatment.

Pubertal timing. Girls enter puberty 1 to 2 years earlier than boys. Because puberty itself drives a GH surge, a girl presenting with poor growth at age 10 to 11 may be harder to evaluate accurately during early pubertal transition. Clinicians may need to prime with low-dose estrogen before stimulation testing to avoid false-positive GHD diagnoses in peripubertal girls, a practice endorsed in the Growth Hormone Research Society Consensus Statement.

Estrogen and IGF-1. Estrogen increases GH secretion but paradoxically causes partial GH resistance at the liver, lowering IGF-1 for a given GH level. This means IGF-1 reference ranges must be interpreted with age- and sex-specific normative data. Using male-derived or mixed-sex norms will underestimate GH adequacy in adolescent girls.

Growth velocity norms. Normal growth velocity charts are sex-specific. Girls grow faster between ages 10 and 13; boys between 12 and 15. A girl growing 4 cm per year at age 11 may be significantly below her expected velocity even if her absolute height looks acceptable to an untrained eye.

Off-Label Sermorelin: The Evidence Base in Pediatric Girls and Boys

The evidence for sermorelin in pediatric GHD comes primarily from trials conducted between 1992 and 2000, when Geref was still on the market. These studies enrolled mostly prepubertal children, with girls comprising roughly 30 to 40 percent of participants, a representation that was better than many drug trials of that era but still insufficient to generate sex-stratified efficacy and safety data with statistical confidence.

Key Trials

Ross et al., 1997. This randomized, open-label multicenter trial compared sermorelin 30 mcg/kg/day to GH 0.3 mg/kg/week in 233 prepubertal children with GHD. After 12 months, mean height velocity increased from 3.9 cm/year to 8.1 cm/year in the sermorelin group, compared to 8.6 cm/year in the rhGH group (not statistically different). IGF-1 normalization was achieved in 68 percent of sermorelin patients versus 82 percent of rhGH patients.

Thorner et al., 1996. A 2-year extension study showed that growth velocity gains with sermorelin were maintained into the second year, though the catch-up growth rate slowed, as expected with any GH-axis therapy. Adult height predictions improved by a mean of 4.2 cm over the untreated projected height, a meaningful but modest gain compared to rhGH data showing 5 to 7 cm adult height improvement.

The Evidence Gap for Girls Specifically

No published trial has reported sermorelin outcomes stratified by sex with adequate statistical power. The available data allow only the following conclusions for girls:

1. Girls in mixed-sex trials achieved growth velocity improvements broadly similar to boys, but no formal test of interaction has been published.
2. Estrogen-related GH sensitivity differences mean girls in early or mid-puberty may respond to lower weight-based doses than the standard 30 mcg/kg, though no dose-finding trial has tested this directly.
3. Girls who begin sermorelin therapy close to menarche have a shorter treatment window before epiphyseal fusion ends efficacy. Bone age assessment every 6 months is especially important in adolescent girls to avoid prolonged therapy after growth plates close.

This constitutes a genuine evidence gap that WomanRx believes every mother and female patient deserves to hear plainly, not buried in fine print.

Dosing and Administration for Pediatric Use

Sermorelin is administered as a subcutaneous injection once nightly, timed to coincide with physiologic nocturnal GH pulsatility. The most commonly cited off-label dose in current compounded formulations is 20 to 30 mcg/kg per injection, given 6 to 7 nights per week.

Because sermorelin is no longer commercially manufactured under an FDA-approved NDA, all current pediatric prescriptions require compounding pharmacies, most operating under 503B outsourcing facility registration. Quality and potency can vary between compounders. Parents should ask the prescriber to confirm the pharmacy holds current 503B status with the FDA.

Injection Technique for Families

• Rotate injection sites among the abdomen, outer thigh, and upper arm to reduce lipohypertrophy.
• Inject at approximately the same time each night, ideally 30 to 60 minutes before sleep onset.
• Refrigerate reconstituted sermorelin; discard unused portions after the manufacturer-specified window (typically 14 to 21 days, check with your compounding pharmacy).
• A child old enough to understand should be taught the injection process to build autonomy and reduce anxiety.

Monitoring Requirements: What Must Happen and When

Monitoring sermorelin therapy in a child is not optional follow-up. It is the mechanism by which you and the prescriber confirm the drug is working, catch side effects early, and know when to stop. The absence of a current FDA label means no mandated monitoring schedule exists, so the following is drawn from rhGH monitoring guidelines adapted for GHRH-analog therapy and published expert opinion.

Every 3 Months

• Height and weight measurement. Growth velocity (cm per year) is the primary efficacy endpoint. Annualized growth velocity below 2 cm/year despite 6 months of therapy warrants reassessment of the diagnosis.
• IGF-1 and IGFBP-3. These should be maintained within the age- and sex-specific normal range. Levels consistently above the 97th percentile suggest over-stimulation and require dose reduction. The Endocrine Society recommends keeping IGF-1 within the normal reference range for age and sex throughout GH-axis therapy.
• Injection site assessment. Inspect for lipohypertrophy, nodules, or signs of local infection.

Every 6 Months

• Bone age X-ray (left hand/wrist). This is non-negotiable, particularly in girls. Bone age advancement greater than chronological age advancement suggests accelerated epiphyseal maturation, which may shorten the effective treatment window and require therapy adjustment.
• Fasting glucose or HbA1c. GH-axis stimulation causes transient insulin resistance. A meta-analysis in the Journal of Clinical Endocrinology and Metabolism found a modest but statistically significant increase in fasting glucose in children receiving rhGH; the same risk applies to sermorelin. Children with a family history of type 2 diabetes or obesity warrant closer glucose surveillance.
• Thyroid function (TSH, free T4). GH-axis activation can unmask central hypothyroidism or reduce T4 levels by increasing T4-to-T3 conversion. Uncontrolled hypothyroidism blunts response to sermorelin. The Endocrine Society guideline recommends checking thyroid function within the first 3 months of therapy and then every 6 months.

Annually

• Bone density assessment. Relevant primarily for children with a prolonged pre-treatment deficit or coexisting conditions affecting bone accrual.
• Lipid panel. GH improves lipid profiles in most children; a baseline and annual check documents metabolic benefit and flags outliers.
• Formal assessment of pubertal stage (Tanner staging). In girls, progression through Tanner stages signals the narrowing treatment window. Once Tanner stage 4 to 5 breast development is reached and menarche has occurred, epiphyseal closure may be 1 to 3 years away.

When to Stop Sermorelin Therapy

Therapy ends when the bone age reaches approximately 14 to 15 years in girls (typically corresponding to at least Tanner stage 4 and post-menarchal status) or 16 to 17 years in boys, or when growth velocity falls below 2 to 2.5 cm per year. Continuing sermorelin after epiphyseal closure produces no height benefit and exposes the child to cost and injection burden without gain.

Some children with GHD require reassessment in young adulthood to determine if GH deficiency persists, since childhood GHD may be transient or permanent. Girls transitioning into adulthood should have this conversation with their pediatric endocrinologist before the transition to adult care.

Pregnancy, Lactation, and Contraception: Required Safety Information

Sermorelin is contraindicated in pregnancy. No adequate human studies of sermorelin in pregnant women exist. Animal data show potential for fetal harm at doses that stimulate excessive GH pulsatility. Sermorelin should be discontinued before a planned conception.

For adolescent girls on sermorelin who become sexually active, contraception counseling is mandatory. The prescribing clinician must discuss reliable contraception methods appropriate to the adolescent's age, health status, and preferences. ACOG recommends long-acting reversible contraception (LARC) as first-line for adolescents who desire contraception, given typical-use failure rates below 1 percent. ACOG Committee Opinion 735 supports offering implants and IUDs to adolescents without restriction based on age or parity.

Lactation. Sermorelin transfer into human breast milk has not been studied. The molecular weight (3,357 daltons) suggests limited transfer, but because no data exist and the potential for GH-axis effects in a nursing infant cannot be excluded, sermorelin should not be used by breastfeeding mothers. This applies primarily to women using sermorelin themselves (an off-label adult use covered separately), not to children receiving the drug. However, a postpartum woman whose daughter is being treated with sermorelin and who is herself breastfeeding a younger sibling should not receive sermorelin for her own conditions during that period.

For mothers asking about their own sermorelin use: If you are taking sermorelin for adult off-label indications and discover you are pregnant, stop the drug immediately and contact your prescriber. Do not restart until after delivery and the cessation of breastfeeding, at minimum.

Who Is a Candidate for Off-Label Sermorelin in Pediatric GHD?

Off-label sermorelin may be considered for a child when all of the following apply:

• Confirmed GHD by two pharmacologic stimulation tests with peak GH below 10 ng/mL, or a single test in the context of a structural lesion or genetic diagnosis.
• Open epiphyses confirmed on bone age X-ray.
• A pediatric endocrinologist has documented the off-label status and discussed it with the family.
• The family has access to a reputable 503B compounding pharmacy and can commit to the monitoring schedule above.
• The child does not have active malignancy (a contraindication shared with rhGH given theoretical concerns about GH-axis stimulation in cancer).

Sermorelin is not appropriate for:

• A child with closed epiphyses.
• A child with active or recent cancer.
• A pregnant adolescent.
• A child whose growth failure has another correctable cause (hypothyroidism, celiac disease, poorly controlled asthma or inflammatory bowel disease) that has not been addressed first.
• Families unable to commit to monitoring, because unmonitored therapy removes the safety net.

A Note on Girls With PCOS and GH-Related Concerns

Girls diagnosed with polycystic ovary syndrome (PCOS) in adolescence sometimes present with short stature or slow growth velocity, but this is rarely caused by true GHD. PCOS is associated with elevated endogenous IGF-1 and increased androgen-driven GH secretion, meaning these girls are more likely to have relative GH excess than deficiency. Using sermorelin in a girl with PCOS and elevated IGF-1 could worsen androgen production and metabolic risk. Sermorelin is not indicated and is potentially harmful in adolescent girls with PCOS unless GHD has been definitively confirmed by stimulation testing and IGF-1 is truly low for age.

What Mothers Are Asking: The Questions You Deserve Straight Answers To

Parents researching sermorelin for their child encounter significant marketing noise, particularly from wellness clinics that promote compounded peptides for adult anti-aging indications and extend those claims to children without adequate evidence. The straightforward answer to the most common questions appears below.

Is sermorelin as effective as rhGH for pediatric GHD? Based on the Ross et al. 1997 trial, first-year growth velocity is comparable. Adult height data are less complete for sermorelin than for rhGH, where decades of post-marketing data support a mean adult height gain of 5 to 7 cm over predicted height.

Is sermorelin safer than rhGH? The theoretical safety advantage is preservation of pituitary feedback, which may prevent supraphysiologic GH peaks. Documented adverse events with sermorelin at therapeutic doses are rare and include mild injection-site reactions, transient headache, flushing, and, rarely, antibody formation that may reduce efficacy. The FDA adverse event database does not show a significantly different safety profile from rhGH at equivalent doses, though direct comparative safety trials are absent.

Can a girl take sermorelin through puberty? Yes, if the diagnosis is confirmed and bone ages are monitored. Estrogen during puberty will naturally accelerate growth plate closure, so treatment time is finite. A girl who starts sermorelin at age 9 may have 3 to 5 years of treatment window; one who starts at age 13 may have 1 to 2 years.